CDYL2 and breast cancer: The overexpression of CDYL2 induces EMT and CSC maintenance in MCF7 and MDA-MB-231 breast cancer cells by increasing the Ser536 phosphorylation of p65 and STAT3 activity by Tyr705 phosphorylation, implicating both the NF-kB and STAT3 signaling pathways [128,168].